Summary of Study ST001903
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001198. The data can be accessed directly via it's Project DOI: http://dx.doi.org/10.21228/M8VD7F This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001903 |
| Study Title | Effect of ketogenic diet on the plasma and tumor metabolome of melanoma-bearing mice |
| Study Type | Metabolomics analysis |
| Study Summary | Growing evidence supports the use of low-carbohydrate/high-fat ketogenic diets (KDs) together with standard therapies to improve cancer treatment outcomes. However, conflicting data exist regarding the efficacy of KDs in melanoma, the deadliest skin cancer. Here, we show that two different KD formulations effectively reduced tumor growth in immunocompromised mice bearing genetically and metabolically heterogeneous human melanoma xenografts. Furthermore, the KDs exerted a metastasis-reducing effect in an immunocompetent syngeneic melanoma mouse model. Ketone bodies did not directly influence melanoma cell proliferation; therefore, we performed an in-depth metabolomics analysis using the MxP® Quant 500 kit combined with a acylcarnitine assay (biocrates life sciences ag)to elucidate potential anti-tumor mechanisms in vivo. Targeted analysis of plasma and tumor metabolomes revealed distinct changes in amino acid metabolism induced by the KDs. Moreover, the KDs increased sphingomyelin synthesis and hydroxylation of certain lipids. Thus, KDs simultaneously affect multiple metabolic pathways to create an unfavorable environment for melanoma cell proliferation, supporting their potential as a complementary nutritional approach to melanoma therapy. |
| Institute | University Hospital of the Paracelsus Medical University Salzburg |
| Last Name | Weber |
| First Name | Daniela |
| Address | Müllner Hauptstraße 48, 5020 Salzburg, Austria |
| d.weber@salk.at | |
| Phone | 0043 57255 26274 |
| Submit Date | 2021-08-10 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS/MS(Dir. Inf.) |
| Release Date | 2022-07-11 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN003815 | AN003816 | AN003817 |
|---|---|---|---|
| Analysis type | MS | MS | MS |
| Chromatography type | Reversed phase | None (Direct infusion) | Reversed phase |
| Chromatography system | Waters Acquity | Waters Acquity | Thermo Dionex Ultimate 3000 |
| Column | MxP Quant 500 Kit System | MxP Quant 500 Kit System | Biocrates Acylcarnitine |
| MS Type | ESI | ESI | ESI |
| MS instrument type | Triple quadrupole | Triple quadrupole | Triple quadrupole |
| MS instrument name | Waters TQ-S MS | Waters TQ-S MS | Thermo TQS Vantage |
| Ion Mode | POSITIVE | UNSPECIFIED | POSITIVE |
| Units | uM | uM | uM |
Chromatography:
| Chromatography ID: | CH002822 |
| Instrument Name: | Waters Acquity |
| Column Name: | MxP Quant 500 Kit System |
| Chromatography Type: | Reversed phase |
| Chromatography ID: | CH002823 |
| Instrument Name: | Waters Acquity |
| Column Name: | MxP Quant 500 Kit System |
| Chromatography Type: | None (Direct infusion) |
| Chromatography ID: | CH002824 |
| Instrument Name: | Thermo Dionex Ultimate 3000 |
| Column Name: | Biocrates Acylcarnitine |
| Chromatography Type: | Reversed phase |
